Mountain Vista Medical Center, Mesa Arizona, USA.
Medigan Army Medical Center WA, USA.
Ann Hepatol. 2024 Nov-Dec;29(6):101544. doi: 10.1016/j.aohep.2024.101544. Epub 2024 Aug 29.
Metabolic dysfunction-associated steatotic liver disease (MASLD) formerly known as Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease. Identifying MASLD risk factors could help early intervention and reduce the burden of the disease. Previous studies investigated the association between sarcopenia and NAFLD. Several trials were published after the last meta-analysis with indecisive results. This is an updated meta-analysis which aims to assess the association between sarcopenia, MASLD, and MASLD-related fibrosis.
Relevant trials published on PubMed, Web of Science, Scopus, and Cochrane Library databases until October 2022 were included. We included studies in which skeletal mass index (SMI) or sarcopenia was compared between patients with and without NAFLD now MASLD. Also, studies comparing fibrosis between MASLD patients with and without sarcopenia were included. Data were pooled as odds ratios (ORs) and 95 % confidence intervals (CIs) using Review Manager Software.
A total of 25 studies were included. The incidence of sarcopenia was significantly higher in MASLD than controls (OR, 1.25; 95 % CI, 1.08-1.44; P = 0.003). SMI odds showed no significant difference between MASLD patients and controls (OR, 1.02; 95 % CI, 0.91-1.15; P = 0.7). MASLD patients with sarcopenia had higher odds of fibrosis than MASLD patients without sarcopenia (OR, 1.49; 95 % CI, 1.03-2.14; P = 0.03).
Sarcopenia increased MASLD's probability and was associated with a higher probability of liver fibrosis in MASLD patients. However, SMI had no predictive value of MASLD occurrence.
代谢功能障碍相关的脂肪性肝病（MASLD）以前称为非酒精性脂肪性肝病（NAFLD），是一种常见的慢性疾病。识别 MASLD 的危险因素有助于早期干预，减轻疾病负担。以前的研究探讨了肌少症与 NAFLD 的关系。在最后一次荟萃分析之后，发表了几项试验，但结果尚无定论。这是一项更新的荟萃分析，旨在评估肌少症、MASLD 和 MASLD 相关纤维化之间的关系。
纳入了截至 2022 年 10 月在 PubMed、Web of Science、Scopus 和 Cochrane Library 数据库上发表的相关试验。我们纳入了比较非酒精性脂肪性肝病（现在 MASLD）患者和非 MASLD 患者之间骨骼质量指数（SMI）或肌少症的研究。还纳入了比较 MASLD 患者和非肌少症患者之间纤维化的研究。使用 Review Manager 软件汇总数据作为比值比（OR）和 95%置信区间（CI）。
共纳入 25 项研究。MASLD 患者的肌少症发生率明显高于对照组（OR，1.25；95%CI，1.08-1.44；P = 0.003）。MASLD 患者和对照组之间的 SMI 比值无显著差异（OR，1.02；95%CI，0.91-1.15；P = 0.7）。有肌少症的 MASLD 患者发生纤维化的可能性高于无肌少症的 MASLD 患者（OR，1.49；95%CI，1.03-2.14；P = 0.03）。
肌少症增加了 MASLD 的可能性，并与 MASLD 患者的肝纤维化可能性增加相关。然而，SMI 对 MASLD 发生无预测价值。
